Filing Details

Accession Number:
0001127602-23-018423
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-06-09 16:16:06
Reporting Period:
2023-06-07
Accepted Time:
2023-06-09 16:16:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
313143 Haemonetics Corp HAE Surgical & Medical Instruments & Apparatus (3841) 042882273
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1420910 W Stewart Strong 125 Summer Street
Boston MA 02110
President, Global Hospital No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-06-07 4,483 $56.57 21,630 No 4 M Direct
Common Stock Acquisiton 2023-06-07 2,410 $57.60 24,040 No 4 M Direct
Common Stock Disposition 2023-06-07 5,053 $88.00 18,987 No 4 F Direct
Common Stock Disposition 2023-06-07 2,538 $88.04 16,449 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-qualified Stock Option (Right to Buy) Disposition 2023-06-07 4,483 $0.00 4,483 $56.57
Common Stock Non-qualified Stock Option (Right to Buy) Disposition 2023-06-07 2,410 $0.00 2,410 $57.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
4,483 2023-05-18 2028-05-18 No 4 M Direct
7,231 2023-05-16 2029-05-16 No 4 M Direct
Footnotes
  1. This number includes unvested restricted stock units ("RSUs") previously reported.
  2. Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.96 to $88.12, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this report.
  4. Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.